Single atom catalysts (SACs) with the maximized metal atom efficiency have sparked great attention. However, it is challenging to obtain SACs with high metal loading, high catalytic activity, and ...good stability. Herein, we demonstrate a new strategy to develop a highly active and stable Ag single atom in carbon nitride (Ag‐N2C2/CN) catalyst with a unique coordination. The Ag atomic dispersion and Ag‐N2C2 configuration have been identified by aberration‐correction high‐angle‐annular‐dark‐field scanning transmission electron microscopy (AC‐HAADF‐STEM) and extended X‐ray absorption. Experiments and DFT calculations further verify that Ag‐N2C2 can reduce the H2 evolution barrier, expand the light absorption range, and improve the charge transfer of CN. As a result, the Ag‐N2C2/CN catalyst exhibits much better H2 evolution activity than the N‐coordinated Ag single atom in CN (Ag‐N4/CN), and is even superior to the Pt nanoparticle‐loaded CN (PtNP/CN). This work provides a new idea for the design and synthesis of SACs with novel configurations and excellent catalytic activity and durability.
A new Ag single atom in carbon nitride (Ag‐N2C2/CN) photocatalyst with Ag‐N2C2 configuration is developed. It affords fast charge transfer, high Ag loading, and good stability. Noteworthily, the Ag‐N2C2/CN exhibits much better hydrogen evolution activity than Ag‐N4/CN, and even superior to the platinum‐loaded CN.
Full text
Available for:
BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK
Recent studies in animal models and humans show that long non-coding RNAs (lncRNAs) are involved in the development of atherosclerosis, which contributes to the pathological foundation of coronary ...artery disease (CAD). LncRNAs in plasma and serum have been considered as promising novel biomarkers for diagnosis and prognosis of cardiovascular diseases, especially CAD. We here measured the circulating levels of 8 individual lncRNAs which are known to be relevant to atherosclerosis in the plasma samples from 300 patients with CAD and 180 control subjects by using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) methods. We found that the plasma level of H19 and long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR) were significantly increased in patients with CAD. The area under the receiver operating characteristic curve was 0.631 for H19 and 0.722 for LIPCAR. Multivariate logistic regression analyses indicated that plasma H19 and LIPCAR were independent predictors for CAD, even after adjustment for traditional cardiovascular risk factors. Further studies identified that plasma levels of H19 and LIPCAR were also increased in CAD patients with heart failure compared to those with normal cardiac function. Taken together, our results suggest that increased plasma levels of H19 and LIPCAR are associated with increased risk of CAD and may be considered as novel biomarkers for CAD.
Full text
Available for:
IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK
Display omitted
•Cu2O/BiVO4 photocatalyst was synthesized under mild conditions.•It shows high catalytic activity for the simultaneous removal of dyes and Cr(VI).•The degradations of cationic and/or ...anionic dyes operate under neutral condition.•A synergistic photoreduction–oxidation mechanism is proposed.
We synthesized Cu2O/BiVO4 composites by growing Cu2O nanoparticles on BiVO4 under mild condition. The optimized composite shows high photocatalytic efficiency in the simultaneous oxidation of organic dyes and reduction of Cr(VI) in neutral media. The XPS results confirm that the Cr(VI) adsorbed on Cu2O/BiVO4 was completely reduced to Cr(III). The photocatalyst can be used for the degradation of cationic or anionic dyes as well as a mixture of them under visible light irradiation. The photocatalytic activity of the composite can be ascribed to the heterojunctions between Cu2O and BiVO4, which facilitate the separation of photogenerated electrons and holes. The work demonstrates that the as-synthesized Cu2O/BiVO4 composite is a promising photocatalyst for the treatment of wastewater that contains organic dyes and Cr(VI) ions.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
Zeolitic imidazolate frameworks-8 (ZIF-8)/polymer composite membranes have shown great promise in gas separation, catalysis and biotechnology due to their microporous nature. However, the structural ...instability against protonation limits the application of ZIF-8 materials in aqueous environments, e.g. water treatment membranes. In this study, a ZIF-8 nanocomposite membrane with satisfactory hydrostability was explored. More specifically, a series of composite ZIF-8 thin film containing DNA molecules were deposited on dopamine-modified polysulfone (PSF) substrates via an in situ growth under ambient conditions. The incorporation of DNA molecules significantly enhanced the hydrophilicity of the composite membrane (water contact angle reduced from 66.9° to 29.2°). Compared with the pure ZIF-8 counterpart, the DNA-containing ZIF-8 membrane exhibited higher water flux, accompanied with higher rejections for organic dyes and inorganic salt ions. More importantly, the DNA-containing ZIF-8 membrane showed significantly enhanced water stability and anti-fouling property during the filtration tests. The utilization of biomacromolecules to stabilize ZIF membrane enables potential applications for ZIF membranes for wider water-related applications.
Display omitted
•Biomolecule modified ZIF-8 membranes are fabricated via an in situ growth strategy.•The introduction of DNA significantly enhances the hydrophilicity of membrane.•The DNA@ZIF-8/L-PDA/PSF membrane shows enhanced water stability.•The DNA-containing ZIF-8 membrane exhibits improved NF efficiency.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Till now, the novel Mg alloys acting as the medical materials have drawn much attention, due to their spontaneous degradability, favorable mechanical properties and the excellent biocompatibilities. ...Unfortunately, they were inevitably affected by flow erosion, corrosion fatigue, stress-interaction and dynamic wear under the human body conditions, leading to significant mechanical-performance attenuation and premature fracture failure. Thus, how to explore and obtain the biomedical Mg-based alloys with controllable degradation rate and suitable biocompatibility was the key issue. Surface modification is a typical method to improve the corrosion resistance. It can isolate the Mg-matrix from the electrolyte by establishing the corrosion barrier without changing the microstructure characteristics. Also, it can change the layer structure and further enhance the degradation behaviors and biological activities of biomedical Mg alloys. In this text, the latest research progresses of surface modification for Mg alloys were reviewed, and the formation mechanism, film layer features as well as the rupture mechanism of conversion coatings were revealed. Besides, the interaction roles of Mg-matrix/modified-layer and modified-layer/electrolyte were analyzed through the comparison of film-layer structure, morphology and the establishment of degradation rates for various modified Mg alloys. Moreover, the internal relationships between the biological biocompatibilities and degradation rates in different corrosive conditions were deeply explored. Finally, the problems of surface modification on biomedical Mg alloys were proposed and the future development directions were prospected.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
KRASG12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach ...requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proved feasible for inhibiting mutant KRAS in vitro; however, it is uncertain whether this approach would translate to in vivo. Here, we describe structure-based design and identification of ARS-1620, a covalent compound with high potency and selectivity for KRASG12C. ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression. We use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo. This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.
Display omitted
•ARS-1620, an atropisomeric selective KRASG12C inhibitor with desirable PK•ARS-1620 selectively induces tumor regression in patient-derived tumor models•KRAS dependency is more profound in vivo compared to 2D-monolayer cell culture•ARS-1620 is a valuable pharmacological tool to interrogate KRAS biology in vivo
A covalent inhibitor specific for G12C mutant KRAS induces tumor regression in in vivo models.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
•Green tea consumption is inversely associated with the risk of stroke.•Moderate green tea drinking (500-1000 ml/d) was associated with a 21% to 24% lower risk of stroke.•Green tea consumption is a ...modifiable dietary risk factor in lowering stroke risk.
Epidemiologic studies are inconsistent regarding the association between green tea consumption and the risk of stroke. We performed a meta-analysis to determine whether an association exists between them in cohort studies.
We searched the PubMed and Embase databases for studies conducted from 1966 through September 2022. Prospective cohort studies that provided relative risk (RR) estimates with 95% confidence interval (CI)s for the association were included. Study-specific risk estimates were combined by using a random-effects model.
A total of five studies, with 11 421 stroke cases among 645 393 participants, were included in the meta-analysis. The summary RR indicated a significant association between highest green tea consumption and reduced risk of stroke (summary RR: 0.74; 95% CI, 0.66–0.83). In the dose-response analysis, we observed a nonlinear association between green tea consumption and the risk of stroke (P for nonlinearity = 0.0000). Compared with non-consumers, the RRs (95% CI) of stroke across levels of green tea consumption were 0.91 (0.89–0.94) for 150 mL/d, 0.84 (0.80–0.89) for 300 mL/d, 0.79 (0.74–0.84) for 500 mL/d, 0.77 (0.72–0.82) for 900 mL/d, and 0.84 (0.77–0.91) for 1500 mL/d.
This meta-analysis suggests that green tea consumption is inversely associated with the risk of stroke, especially among those with moderate consumption. Our results support recommendations for green tea consumption to the primary prevention of stroke.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered ...for cancers with KRAS mutations. Here, we describe ARS-853, a selective, covalent inhibitor of KRAS(G12C) that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation. Based on the rates of engagement and inhibition observed for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRAS(G12C) is in a state of dynamic flux that can be modulated by upstream signaling factors. These studies provide convincing evidence that the KRAS(G12C) mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.
A cell-active, mutant-specific, covalent inhibitor of KRAS(G12C) is described that targets the GDP-bound, inactive state and prevents subsequent activation. Using this novel compound, we demonstrate that KRAS(G12C) oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.
PDF
